Skip to main content

Table 2 AgeCoDe cohort patient demographics

From: Alzheimer’s disease-specific transcriptomic and epigenomic changes in the tryptophan catabolic pathway

 

Controls

AD Converters

Baseline (T1)

 N

42

54

 Age at baseline

81.00 ± 3.11

82.31 ± 3.55

 Gender (male/female)

10/32

17/37

 IDO2 (cg11251498) (%)

72.53 ± 5.36

75.59 ± 3.71

Follow-up (T2)

 N

42

41

 Age at baseline

81.00 ± 3.11

82.01 ± 3.51

 Gender (male/female)

10/32

13/28

 IDO2 (cg11251498) (%)

73.07 ± 4.91

75.25 ± 4.96

  1. Overview of patient characteristics in the AgeCoDe cohort used in this study. Data are presented in n or mean ± SD. Patients were age- and gender-matched. Blood was collected at baseline and follow-up (average 4.5 years). All patients were controls at baseline and the patients were followed-up over time
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193